Search PubMed⌕ Search

Biomedical subjects

T J Phillips

Publications and source records attributed to T J Phillips.

196 records · Page 11Linked to original sources
PubMedDate not supplied

Quantitative trait loci associated with brain weight in the BXD/Ty recombinant inbred mouse strains.

Adult C57BL/6J (B6) male mice had 37% heavier brains than did DBA/2J (D2) mice, while their body weights did not differ. The BXD recombinant inbred (RI) series of 20 strains, derived from a cross between B6 and D2 inbred strains, was used as the initial screen to determine significant associations between male brain weight and brain:body weight ratio, with allelic variation at 360 known marker gene loci. For brain weight, this yielded five candidate chromosome regions, each reflecting a possible quantitative trait locus (QTL) site affecting brain weight. The second step was to test as many of these five as possible using standard (non-RI) inbred strain data for brain weight previously reported in the literature. For this purpose, only strains possessing the same alleles as the B6 or D2 strains were used. Sufficient data to test two of the five candidate QTL were available. Of these, one was strongly supported as a site affecting brain weight--the D7rp2 region of chromosome 7. For the brain to body weight ratio, four chromosome regions emerged as significantly associated in the BXD series, but none were amenable to testing due to a lack of allelic information for the standard inbred strains. However, two of these regions showed highly significant associations (p less than 0.001, single test) that merit consideration as QTL sites for future testing. These two are the Hba region on chromosome 11 and the D17Tu7 region on chromosome 17. The genetic correlation between brain and body weight was low (r = 0.28), indicating that these two traits are largely genetically independent in the BXD RI series.

Animals↗
PubMedDate not supplied

An evaluation of the role of ethanol clearance rate in the differential response of long-sleep and short-sleep mice to ethanol.

Ethanol (ETOH) clearance rates were determined in Long-Sleep (LS) and Short-Sleep (SS) mice, which were selectively bred for differential soporific response to ETOH. Determination of blood ethanol levels at 45 min intervals following administration of 3.8 g/kg IP indicated that SS mice clear ETOH at a faster rate. Repeatedly sampled mice of each line cleared ETOH more slowly than those where samples were taken only once. A second experiment utilized pairs of LS and SS mice matched on body weight. These were treated with one of several doses of ETOH, and duration of loss of the righting reflex measured for one member of the pair. Blood ETOH levels were determined in samples taken from both members of the pair when the tested member regained the righting reflex. LS mice had small but consistently higher blood ETOH levels in these pairs. The magnitude of the differences between the LS and SS mice in these experiments indicate that clearance rate differences can account for only a small portion of the differences in behavioral responses of these mice to ETOH.

Animals↗
PubMedDate not supplied

A comparison of ethanol absorption and narcosis in long- and short-sleep mice following intraperitoneal or intragastric ethanol administration.

Blood ethanol concentrations (BEC) were determined in Long-Sleep (LS) and Short-Sleep (SS) mice during a 30 min period following ethanol (ETOH) administration. Absorption of ETOH was rapid and followed a similar time course in the two lines after intraperitoneal (IP) administration of 3.8 or 4.5 g/kg. Following intragastric (IG) administration, slower absorption and lower peak BECs were noted in both lines, but in LS mice this effect was more pronounced. The two routes of administration were not effective in altering duration of loss of the righting reflex (LRR), or waking BECs following 4.5 g/kg ETOH. LS mice had the expected longer LRR durations and lower BECs at waking than did SS mice. Differences in absorption rate and peak BEC are concluded to be unrelated to ETOH neurosensitivity in these mice.

Animals↗
PubMedDate not supplied

Ozone emissions from a "personal air purifier".

Ozone emissions were measured above a "personal air purifier" (PAP) designed to be worn on a lapel, shirt pocket, or neck strap. The device is being marketed as a negative ion generator that purifies the air. However, it also produces ozone within the person's immediate breathing zone. In order to assess worst-case potential human exposure to ozone at the mouth and nose, we measured ozone concentrations in separate tests at 1, 3, 5, and 6 in. above each of two PAPs in a closed office. One PAP was new, and one had been used slightly for 3 months. Temperature, relative humidity, atmospheric pressure, room ozone concentration, and outdoor ozone concentration also were measured concurrently during the tests. Average ozone levels measured directly above the individual PAPs ranged from 65-71 ppb at 6 in. above the device to 268-389 ppb at 1 in. above the device. Ozone emission rates from the PAPs were estimated to be 1.7-1.9 microg/minute. When house dust was sprinkled on the top grid of the PAPs, one showed an initial peak of 522 ppb ozone at 1 in., and then returned to the 200-400 ppb range. Room ozone levels increased by only 0-5 ppb during the tests. Even when two PAPs were left operating over a weekend, room ozone levels did not noticeably increase beyond background room ozone levels. These results indicate that this "PAP," even without significant background ozone, can potentially elevate the user's exposures to ozone levels greater than the health-based air quality standards for outdoor air in California (0.09 ppm, 1-hour average) and the United States (0.08 ppm, 8-hour average).

Air Pollutants↗
PubMedDate not supplied

Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers.

About 600,000 people in the United States are estimated to be affected by venous ulcers. The cornerstone of care of chronic venous ulcers involves the application of compression bandages. Other therapies include treatment of associated infection, treatment for edema and inflammation, and debridement when necessary. Repifermin, a recombinant human KGF-2 (fibroblast growth factor-10), exerts a proliferative effect on epithelial cells, in vitro and in vivo, and has been shown to accelerate wound healing in several experimental animal models. A randomized, double-blind, parallel-group, placebo-controlled, multicenter study was conducted to evaluate the safety and efficacy of topical repifermin treatment, for 12 weeks, in the healing of chronic venous ulcers in 94 patients. Repifermin was shown to accelerate wound healing, with significantly more patients achieving 75% wound closure with repifermin than with placebo. The treatment effect appeared more marked for a subgroup of patients with initial wound areas < or = 15 cm2 and wound ages of < or = 18 months. A longer duration of treatment (e.g., 26 weeks) may allow better differentiation of the benefit of repifermin compared with placebo, particularly with respect to complete wound closure. The safety assessment showed that repifermin was well tolerated.

Administration, Topical↗
PubMedDate not supplied

Cost effectiveness in wound care.

Universal, objective definitions or formulas have not been available for calculating the costs of wounds and measuring cost/benefits of different care methods. Therefore, it is difficult to compare cost effectiveness of different treatments. A literature review revealed confusion concerning the differences between "cost" and "cost effectiveness". The costs of wound care are divided into direct costs (i.e., costs of supplies, surgical interventions, medications, inpatient care) and indirect costs (i.e., assistance with activities of daily living, days lost from work, litigation). Studies of cost effectiveness should measure cost per unit outcome. In wound care studies, outcomes are usually measured according to the goals of treatment. Common problems with published cost effectiveness studies are that cost is often confused with cost effectiveness; there is no standard method of calculating wound care costs; few studies have measured costs to achieve measured treatment outcomes; and outcomes are often measured or reported differently from study to study. In view of this, it is impossible to clarify cost effectiveness of healing, debridement, pain relief, etc. Until universal, objective scales to measure cost effectiveness are available, the clinician must read published studies critically to determine if treatment measures are indeed cost effective.

Cost-Benefit Analysis↗